AI Article Synopsis
- The study evaluates the effectiveness and safety of botulinum toxin type A (BoNT-A) for treating primary plantar hyperhidrosis (PPH), based on the analysis of records from 129 patients over nearly two decades.
- Most patients (89.1%) received onabotulinumtoxin-A, averaging around 2 sessions, with a mean response duration of about 6 months, showing a positive response rate over time.
- The majority of patients reported being satisfied with the treatment, and no serious side effects were noted, indicating that BoNT-A is a viable option for managing PPH.
Article Abstract
Background/objectives: To date, scientific data on the efficacy of botulinum toxin type A (BoNT-A) for primary plantar hyperhidrosis (PPH) are mainly derived from case reports and small case series. Herein, we sought to assess the efficacy and safety of BoNT-A for PPH on a large series of patients.
Methods: Medical records of patients who were referred to the outpatient department for hyperhidrosis of a tertiary care hospital and received BoNT-A for PPH from March 2003 until December 2022 were reviewed.
Results: A total of 129 patients [12 males, 117 females; median age 32 years (range, 16-72)] were included in the study, after excluding 24 patients with insufficient documented follow-up data. Most patients [115 (89.1%)] received onabotulinumtoxin-A, nine (7.0%) abobotulinumtoxin-A and five (3.9%) both in subsequent sessions. The mean number of sessions was 2.02 [standard deviation (SD), 2.29] and the mean duration of response 6.16 months (SD, 4.01). The percentage of response, as evaluated by Minor's test, was 71.67%, 63.44%, 47.78% and 34.13% after 1, 3, 6 and 9 months, respectively. Most patients were satisfied (21.7%) or very satisfied (58.9%) with the treatment. No serious side effects were reported.
Conclusions: The results of this retrospective study suggest that BoNT-A is an effective and safe treatment option for PPH.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ajd.14188 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The influence of pain exacerbation on rear foot eversion and plantar pressure symmetry in women with patellofemoral pain: a cross sectional study.
BMC Musculoskelet Disord
January 2025
Department of Exercise Rehabilitation, Faculty of Sport Sciences, Bu-Ali Sina University, Hamedan, Iran.
Background: The patellofemoral joint (PFJ) stress as a primary mechanical stimulus in the patellofemoral pain (PFP) etiology is affected by plantar pressure symmetry. This study evaluated how pain exacerbation affects rear foot eversion and plantar pressure distribution symmetry.
Method: Sixty women with PFP participated in this study.
Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-The Phase III MECCA Trial.
J Clin Oncol
January 2025
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Purpose: The effects of metronomic chemotherapy plus endocrine therapy have yet to be elucidated through a randomized phase III clinical trial.
Methods: Randomized clinical trials were conducted at 12 centers in China from August 22, 2017, to September 24, 2021, and the final follow-up date was August 25, 2023. Patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) who had no previous systemic therapy in the metastatic setting were enrolled.
Effects of Dry Needling on Gastrocnemius Muscle Spasticity and Gait in Patients with Multiple Sclerosis: A Pilot Randomized Controlled Trial.
Med Acupunct
October 2024
Department of Physiatry and Nursing, Faculty of Health Sciences, University of Zaragoza, Zaragoza, Spain.
Objective: Spasticity is a common complication in patients with multiple sclerosis (pwMS). The present study aimed to evaluate the clinical, biomechanical, and functional effects of dry needling (DN) in treating gastrocnemius muscle spasticity in pwMS.
Materials And Methods: A pilot single-blinded randomized controlled trial was carried out.
A real-world pharmacovigilance study of Sorafenib based on the FDA Adverse Event Reporting System.
Front Pharmacol
December 2024
Department of Gastroenterology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Aims: The primary objective of this study was to closely monitor and identify adverse events (AEs) associated with Sorafenib, a pharmacological therapeutic agent used to treat hepatocellular carcinoma, renal cell carcinoma, and thyroid cancer. The ultimate goal was to optimize patient safety and provide evidence-based guidance for the appropriate use of this drug.
Methods: Reports from the FDA Adverse Event Reporting System (FAERS) database were comprehensively collected and analyzed, covering the first quarter of 2004 to the first quarter of 2024.
Spinal cord epidural stimulation for male sexual function in spinal cord injured rats.
J Sex Med
December 2024
Anatomical Sciences and Neurobiology, University of Louisville School of Medicine, Louisville, KY 40202, United States.
Background: 95% of men with spinal cord injuries exhibit difficulties with sexual function, including erectile dysfunction, anejaculation, retrograde ejaculation, poor ejaculatory force, and poor sperm quality.
Aim: The primary goal is to determine if well-established interventions, such as spinal cord epidural stimulation, are a feasible treatment for sexual dysfunction and if locomotor recovery training can be used to improve ejaculatory function in a rodent model of spinal cord injury (SCI).
Methods: Male Wistar rats underwent thoracic laminectomies (shams), spinal cord transections, or moderate spinal cord contusion injuries.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!